June 4, 2024 6:43am

Expectation will be the word for June; meeting the unknowns with soon to be known will be the subject of investing decisions through these summer months

Pre-open Indication: 2 Sell into Strength, 1 Positive and 1 Negative Indications   

Keep your finger on the sell button, but still keep a buy ticket in the other hand

A daily analytic read-out from RMi is constructed by specific warnings of challenging share pricing situations

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and markets doesn't necessarily translate into actual trading in the today’s market session.

Who is speaking-up for investors? I write this blog/newsletter about – facts in evidence!  

 

Tuesday: The pre-open Dow futures are DOWN -0.47% or (-182 points), the S&P futures are DOWN -0.50% or (-26 points) as the Nasdaq futures are DOWN -0.43% or (-79 points)

Stock futures were lower Tuesday, June 4, 2024

European markets were lower,

Asia Pacific markets were mixed with only Hong Kong up

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies 

Monday: The Dow closed DOWN -115.29 points or -0.30%, the S&P closed UP +5.89 points or +0.11% while the Nasdaq closed UP +93.65 points or +0.56%

Economic Data Docket: Job openings, April (8.3 million expected, 8.48 million prior); Factory orders, April (0.7% expected, 1.6% prior); Durable goods orders, April final (0.7% expected, 0.7% prior)

 

Q2/24: 

June 3 – 1 positive close

  • May – 1 holiday, 11 positive and 11 negative closes
  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength Indication:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Ionis Pharmaceuticals (IONS) closed up +$1.20 after Friday’s +$1.02 with a neutral pre-open indication.

Agenus (AGEN) closed up +$1.28 after Friday’s +$0.58 and Thursday’s +$0.08 with a neutral pre-open after an aftermarket indication of +$0.53 or +3.12%

 

Negative indications:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed up +$0.56 after Friday’s -$0.27 with a neutral pre-open indication after a negative -$0.48 or -1.97% aftermarket indication

 

Positive Indications:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Vericel (VCEL) closed down -$1.35 after Friday’s -$0.48, Thursday’s +$1.44, Wednesday’s -$1.23 and last Tuesday’s -$0.26 with a neutral pre-open indication after a positive +$1.72 or +3.71% aftermarket indication.

 

 

The BOTTOM LINE: Stil hoping for a better June for our universe of cell and gene therapy sector equities, although hope is not a strategy or a technical indicator.

  • June’s 3, the month’s 1st session began with a barely positive close …
  • Recapping May: 1 holiday, 11 positive and 11 negative closes – NOT a great direction showing.
  • I am still expecting a bumpy ride for cell and gene therapy equities as we enter and run-through the month of June.
  • Anyone who reads my posts, knows that I am about making money in a portfolio, no matter what happens in the sector

The stock market rally retreated Monday morning as the ISM manufacturing index unexpectedly fell, signaling a deeper contraction. While that might be good news for inflation, there are growing signs that the U.S. economy is starting to falter. However, as on Friday, the key indexes came off lows to close mixed. <IBD>

  • Be careful, it's not a great time to be adding exposure; however, there are some glaring overbought and a couple of oversold

 

The US economy is no longer shocking Wall Street to the upside. Economic consensus has shifted from forecasters chasing the data higher to scaling back levels of optimism as recent data shows activity cooling across a variety of metrics. This has dampened hopes that economic growth could unexpectedly accelerate for a second straight year. <Yahoo Finance>

  • "I am having trouble getting too excited about the economy. Conditions are fine, but I would hardly describe the situation as consistent with a meaningful acceleration." <Renaissance Macro head of economic research Neil Dutta wrote on Monday>

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.